Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Table 1 Patient demographic and baseline characteristics (full analysis set, N=30)

Characteristics	n	%
Male/female ratio	26/4	86.7:13.3
Age (years)
Median (range)	60 (32–72)
> 65	5	16.7
ECOG performance status
0	3	10.0
1	27	90.0
TNM stage
IV	30	100
CEA(ng/ml)
< 5	2	6.7
5–200	16	53.3
> 200	10	33.3
Unknown	2	6.7
Primary disease site
Colon	13	43.3
Rectum	16	53.3
Colon and rectum	1	3.3
Primary tumor location
Right	4	13.3
Left colon and rectum	26	86.7
Primary tumor resected
Yes	19	63.3
No	11	36.7
Metastatic sites
Liver only	16	53.3
Liver + other	9	30
Other only	5	16.7
Metastatic status
Synchronous	25	83.3
Metachronous	5	16.7
Diameter of the largest target lesions (mm)
median (range)^a	45 (16–122)
MSI/MMR status^b
MSS/pMMR	25	83.3
MSI-H/dMMR	0	0
Unknow	5	16.7

ECOG, Eastern Cooperative Oncology Group; TNM, tumor, node, metastasis; CEA, carcinoembryonic antigen; MSI, micro satellite instability; MMR, mismatch repair
^aThe median is determined by IQR
^bThirteen patients received the MSI test by PCR and MMR test by immunohistochemistry, and 9 patients only received the MMR test by immunohistochemistry and 3 patients only received MSI test by PCR

ISSN: 1741-7015